ABSTRACT
Plants experience constant exposed to diverse abiotic stresses throughout their growth and development stages. Given the burgeoning world population, abiotic stresses pose significant challenges to food and nutritional security. These stresses are complex and influenced by both genetic networks and environmental factors, often resulting in significant crop losses, which can reach as high as fifty percent. To mitigate the effects of abiotic stresses on crops, various strategies rooted in crop improvement and genomics are being explored. In particular, the utilization of biostimulants, including bio-based compounds derived from plants and beneficial microbes, has garnered considerable attention. Biostimulants offer the potential to reduce reliance on artificial chemical agents while enhancing nutritional efficiency and promoting plant growth under abiotic stress condition. Commonly used biostimulants, which are friendly to ecology and human health, encompass inorganic substances (e.g., zinc oxide and silicon) and natural substances (e.g., seaweed extracts, humic substances, chitosan, exudates, and microbes). Notably, prioritizing environmentally friendly biostimulants is crucial to prevent issues such as soil degradation, air and water pollution. In recent years, several studies have explored the biological role of biostimulants in plant production, focusing particularly on their mechanisms of effectiveness in horticulture. In this context, we conducted a comprehensive review of the existing scientific literature to analyze the current status and future research directions concerning the use of various biostimulants, such as plant-based zinc oxide, silicon, selenium and aminobutyric acid, seaweed extracts, humic acids, and chitosan for enhancing abiotic stress tolerance in crop plants. Furthermore, we correlated the molecular modifications induced by these biostimulants with different physiological pathways and assessed their impact on plant performance in response to abiotic stresses, which can provide valuable insights.
ABSTRACT
The present study describes the cloning of the cellobiohydrolase gene from a thermophilic bacterium Clostridium clariflavum and its expression in Escherichia coli BL21(DE3) utilizing the expression vector pET-21a(+). The optimization of various parameters (pH, temperature, isopropyl ß-d-1-thiogalactopyranoside (IPTG) concentration, time of induction) was carried out to obtain the maximum enzyme activity (2.78 ± 0.145 U ml-1) of recombinant enzyme. The maximum expression of recombinant cellobiohydrolase was obtained at pH 6.0 and 70 °C respectively. Enzyme purification was performed by heat treatment and immobilized metal anionic chromatography. The specific activity of the purified enzyme was 57.4 U mg-1 with 35.17% recovery and 3.90 purification fold. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) showed that the molecular weight of cellobiohydrolase was 78 kDa. Among metal ions, Ca2+ showed a positive impact on the cellobiohydrolase enzyme with increased activity by 115%. Recombinant purified cellobiohydrolase enzyme remained stable and exhibited 77% and 63% residual activity in comparison to control in the presence of n-butanol and after incubation at 80 °C for 1 h, respectively. Our results indicate that our purified recombinant cellobiohydrolase can be used in the biofuel industry.
ABSTRACT
[This corrects the article DOI: 10.1039/D1RA00545F.].
ABSTRACT
The treatment protocol of status epilepticus has many associated toxicities so there is interest in alternate nonmedicinal therapies for managing New Onset Refractory Status Epilepticus (NORSE) patients. Vagus nerve stimulation (VNS) is an FDA-approved therapy for refractory epilepsy that has been shown to decrease the frequency and severity of seizures. We present the case of a patient with new-onset refractory status epilepticus (NORSE) whose seizures were successfully treated with vagus nerve stimulation. A 25-year-old male with no history of epilepsy or other neurological disorders presented with altered mental status and generalized tonic-clonic seizures following a two-week history of an upper respiratory tract infection. Lumbar puncture showed neutrophilic pleocytosis, and he was treated for bacterial and viral meningoencephalitis. In spite of treatment, his seizures began increasing in frequency. On day three, the patient entered status epilepticus (SE) refractory to intensive pharmacotherapy with maximal doses of valproate, levetiracetam, and propofol. On day four, SE remained refractory, so pentobarbital was introduced with targeted burst suppression pattern on electroencephalography (EEG). Patient continued to be refractory to these measures, so a vagus nerve stimulator (VNS) was implanted (day eight). Following VNS implantation, EEG demonstrated significant reduction of seizure activity and subsequent magnet swiping continued aborting electrographic seizures. No SE or electrographic seizures were reported for seventy-two hours, but few occasional discharges were reported. Seizures eventually recurred on day fourteen and the patient succumbed to his multiple comorbidities on day seventeen. Due to the efficacy of VNS in refractory epilepsy, there was interest in using it in refractory status epilepticus. Multiple case reports have described a benefit from implantation of VNS in the treatment of SE. The successful use of VNS to acutely terminate status epilepticus for seventy-two hours in this critically ill patient adds to current evidence that there is utility in using VNS for refractory status epilepticus.
